First UPlink infectious disease test is for C difficile
This article was originally published in Clinica
The first infectious disease product to be developed by OraSure Technologies and its partner Meridian Bioscience using the phosphor-based UPlink technology will be a test for Clostridium difficile toxins A and B, which will be used in the diagnosis of C difficile-associated disease. OraSure has already filed for 510(k) approval for UPlink-based assays for cocaine, opiate and amphetamines (see Clinica No 947, p 18).
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.